Loading clinical trials...
Loading clinical trials...
A Prospective, Non-interventional, Multicenter Observational Study to Evaluate Long-term Effectiveness and Safety, Patient Characteristics and Subjective Patient-reported Outcomes of Dupilumab in Patients With COPD Under Real-world Conditions
Conditions
Interventions
Dupilumab
Locations
18
Germany
Investigational Site Number: DE18
Auerbach, Germany
Investigational Site Number: DE21
Augsburg, Germany
Investigational Site Number: DE13
Bad Homburg, Germany
Investigational Site Number: DE19
Berlin, Germany
Investigational Site Number: DE02
Berlin, Germany
Investigational Site Number: DE29
Burgwedel, Germany
Start Date
July 1, 2025
Primary Completion Date
July 1, 2029
Completion Date
July 1, 2029
Last Updated
December 22, 2025
NCT07307781
NCT07509606
NCT07451977
NCT07477600
NCT07382258
NCT07195838
Trial Transparency email recommended (Toll free for US & Canada)
CONTACT
800-633-1610Contact-US@sanofi.comLead Sponsor
Sanofi
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions